Congestive heart failure (CHF) is a clinical syndrome that features a failing heart together with signs and symptoms arising from renal retention of salt and water, mediated by attendant neurohormonal activation, and which prominently includes the renin-angiotensin-aldosterone system. More than this cardiorenal perspective, CHF is accompanied by a systemic illness whose features include an altered redox state in diverse tissues and blood, an immunostimulatory state with proinflammatory cytokines and activated lymphocytes and monocytes, and a wasting of tissues that includes muscle and bone. Based on experimental studies of aldosteronism and clinical findings in patients with CHF, there is an emerging body of evidence that secondary hyperparathyroidism is a covariant of CHF. The aldosteronism of CHF predisposes patients to secondary hyperparathyroidism because of a chronic increase in Ca 2+ and Mg 2+ losses in urine and feces, with a fall in their serum ionized levels and consequent secretion of parathyroid hormone. Secondary hyperparathyroidism accounts for bone resorption and contributes to a fall in bone strength that can lead to nontraumatic fractures. The long-term use of a loop diuretic with its attendant urinary wasting of Ca 2+ and Mg 2+ further predisposes patients to secondary hyperparathyroidism and attendant bone loss. Aberrations in minerals and micronutrient homeostasis that includes Ca 2+ , Mg 2+ , vitamin D, zinc and selenium appear to be an integral component of pathophysiologic expressions of CHF that contributes to its systemic and progressive nature. This broader perspective of CHF, which focuses on the importance of secondary hyperparathyroidism and minerals and micronutrients, raises the prospect that dietary supplements could prove remedial in combination with the current standard of care.
Hear t failure is a worldwide health problem of ever increasing proportions, particularly among the elderly. Both systolic and diastolic left ventricular dysfunction can eventuate in a clinical syndrome having characteristic signs and symptoms, known as congestive heart failure (CHF), which arise from congested organs and hypoperfused tissues. The origins of CHF are rooted in a salt-avid state mediated by neurohormonal activation that includes the reninangiotensin-aldosterone and adrenergic nervous systems.
Beyond this cardiorenal perspective, it is now recognized that CHF syndrome involves more than a failing heart and saltretaining kidneys. CHF is accompanied by a systemic illness that contributes to its progressive nature. It too appears as a result of neurohormonal activation and features oxidative stress in diverse tissues, immune cell activation and a loss of soft tissues and bone that eventuates in a wasting syndrome termed cardiac cachexia. A dyshomeostasis of minerals (Ca 2+ and Mg 2+ ) contribute to the appearance of secondary hyperparathyroidism, while insufficient micronutrients (vitamin D, zinc and selenium) predispose patients to secondary hyperparathyroidism and to reduced antioxidant defenses. Herein, we consider this broader perspective of CHF, its systemic nature and the role of minerals and micronutrients.
CHF: A Salt-Avid State
CHF is a clinical syndrome consisting of signs and symptoms that arise from congested organs and hypoperfused tissues. Its origins are rooted in Na + and water retention, and is characterized by a urinary sodium/potassium (Na/K) ratio of <1.0. CHF has its origin rooted in an activation of several circulating neurohormonal systems, including the renin-angiotensin-aldosterone system and the sympathetic nervous system, which are based on impaired renal perfusion with associated overproduction of angiotensin II, aldosterone and catecholamines. These neurohormones overwhelm the biologic actions of atrial and brain natriuretic peptides that had maintained urinary Na excretion (urinary Na/K >1.0), euvolemia and a state of clinical compensation. Elevations in plasma renin activity, angiotensin II and aldosterone are integral features of the "volume-overloaded" state expressed as expanded intra-and extravascular volumes and the resultant clinical decompensation represented by CHF. 1, 2 The importance of these hormones is underscored by the proven efficacy of pharmacologic interventions that interfere with these hormones. 3, 4 CHF: A Systemic Illness A broader perspective of CHF recognizes its systemic nature which has been described as a neuroendocrine-immune system interface gone awry. 5 This illness includes (1) the presence of oxidative stress with reactive oxygen and nitrogen intermediates that overwhelm endogenous antioxidant defenses in such diverse tissues as skin, skeletal muscle, heart, peripheral blood mononuclear cells (lymphocytes and monocytes) and blood, (2) a proinflammatory phenotype with activated peripheral blood mononuclear cells and elevations in circulating chemokines and cytokines, such as interleukin-6 and tumor necrosis factor (TNF)-α, and (3) a catabolic state with loss of soft tissues and bone due, in part, to negative caloric and nitrogen balance that eventuates in a wasting syndrome termed cardiac cachexia. Factors contributing to the appearance of this systemic illness include secondary hyperparathyroidism, based on urinary and fecal wasting of Ca 2+ and Mg 2+ , and reduced plasma ionized [Ca 2+ ]o and [Mg 2+ ]o which raise plasma parathyroid hormone (PTH) levels. 6 PTH-mediated Ca 2+ overloading of diverse cells, in turn, leads to the induction of oxidative stress. 7 Micronutrient deficiencies also contribute to the induction of oxidative stress by reducing the activity of antioxidant defenses provided by Cu/Zn-superoxide dismutase and Se-glutathione peroxidase. 8 Insights from an Animal Model Experimental studies in rats have focused on one aspect of the renin-angiotensin-aldosterone system activation, namely chronic aldosteronism, where plasma renin activity and angiotensin II are each suppressed, while plasma aldosterone levels are raised to those found in human CHF which are inappropriate for dietary Na + intake consisting of 1% sodium chloride (NaCl) in drinking water. A 0.4% potassium chloride (KCl) supplement is provided to these rats to prevent hypokalemia. Spironolactone, an aldosterone receptor antagonist, can be used as a co-treatment.
Using this rat model of aldosteronism, several aspects of the systemic nature of CHF were elucidated (figure 1). First, aldosterone/salt treatment is accompanied by a marked increase in urinary and fecal excretion of Ca 2+ and Mg 2+ . 6, 9 These losses are found at week 1 of the aldosterone/salt treatment and are sustained over the course of 6 weeks of continuous treatment. For a fixed dietary intake of these divalent cations, their continued loss from both kidneys and colon leads to a fall in plasma ionized [Ca 2+ ]o and [Mg 2+ ]o, each of which are stimuli to the parathyroid glands' release of PTH. Plasma PTH levels are increased throughout the aldosterone/salt treatment in an attempt to restore extracellular levels of these cations. This secondary hyperparathyroidism leads to bone resorption and increased renal and gastrointestinal absorption of Ca 2+ and Mg 2+ promoted by 1,25(OH)2D3. 6, 9, 10 Bone mineral density declines during the course of aldosterone/salt treatment and is accompanied by a reduction in bone strength to resist flexor stress. 6 Elevations in plasma PTH are accompanied by an excessive accumulation of intracellular Ca 2+ in such diverse tissues as heart, skeletal muscle and peripheral blood mononuclear cells. This has been referred to as a Ca 2+ paradox. 11 As is the case with ischemia/reperfusion injury or excess circulating catecholamines, intracellular Ca 2+ overloading is accompanied by the appearance of oxidative stress. This is expressed as (1) an activation of nicotinamide adenosine dinucleotide phosphate oxidase, a source of superoxide in vascular tissues; (2) an activation of a redox-sensitive transcription factor (NF)-κB, together with upregulated expression of the proinflammatory genes it governs; (3) reactive oxygen (e.g., superoxide, H2O2) and nitrogen (e.g., peroxynitrite) species in diverse tissues; and (4) 22 Secondary hyperparathyroidism with hypercalciuria has been observed in patients with advanced CHF awaiting cardiac transplantation and who had received chronic furosemide treatment. 23, 24 These persons were also found to have a reduction in bone mineral density in keeping with osteopenia or, in more advanced cases, with osteoporosis. Among nursing home residents, daily furosemide dosage is an important predictor of secondary hyperparathyroidism. 25 Chronic furosemide treatment, even in the usual dosage of 40 or 80 mg, is also associated with heightened urinary losses of thiamine 26 and ultimately leading to a deficiency of vitamin B1.
In patients with CHF, having reduced effort tolerance because of their limiting symptoms, a housebound lifestyle follows and predisposes them to the appearance of hypovitaminosis D. Reductions in serum 25(OH)D have been reported in some Caucasian patients who were hospitalized in New York City with CHF awaiting transplantation. 24 Hypovitaminosis D has also been found in some non-hospitalized European patients with CHF. 27 In African-Americans, hypovitaminosis D is prevalent. Melanin is a natural sunscreen that requires longer exposure to sunlight for the skin to generate vitamin D. 28 It also absorbs heat and therefore may contribute to an avoidance of sunlight in warm summer months. ]o, have been found in African-Americans hospitalized in Memphis with decompensated failure of ≥4 weeks despite medical treatment, which is in keeping with prolonged activation of the renin-angiotensin-aldosterone system, and in many, but not all African-Americans with treated CHF of shorter duration (1-2 weeks) or in non-heart failure controls (figure 2). PTH levels were not increased in AfricanAmericans with compensated, treated failure or in non-heart failure patients serving as controls. 29, 30 Calculated creatinine clearance ranged between 60 ml/min to 90 ml/min in these African-American patients with either decompensated or compensated heart failure and therefore, marked renal failure (creatinine clearance <30 ml/min) which is accompanied by secondary hyperparathyroidism, does not account for the appearance of secondary hyperparathyroidism. The importance of our findings is further supported by recently published interventional studies with nutrients. [31] [32] [33] Schleithoff et al 31 In addition to compromised stores of vitamins D and B1 in patients with CHF, other micronutrients need to be considered. These include Zn and Se, each of which is integral to the activity of endogenous antioxidant defenses. Obtained primarily from dietary sources, reductions in serum Zn and Se have been associated with the appearance of a dilated cardiomyopathy. [34] [35] [36] [37] Of interest, urinary Zn excretion is increased in response to treatment with angiotensinconverting enzyme inhibitor or angiotensin receptor antagonist and where hypozincemia is held responsible for the appearance of disturbances of taste. [38] [39] [40] [41] In recent studies conducted in Memphis in middle-aged African-American patients having a dilated cardiomyopathy of uncertain etiology, reductions in serum Zn and Se were found and included those patients hospitalized with decompensated failure and outpatients with compensated failure. Specifically, serum Zn was below normal range (75-140 μg/dl) in 11 of 15 patients with protracted CHF (67 ± 5; 47-107 μg/dl), 8 of 10 patients with 1-week to 2-weeks CHF (65 ± 4; 43-79 μg/dl) and 5 of 6 patients with compensated failure (70 ± 2; 63-79 μg/dl). Serum Se (normal range 85-125 μg/l) was reduced in all 15 patients with ≥4 weeks CHF (56 ± 3; 36-72 μg/l), 9 of 10 with short-term CHF (63 ± 4; 45-86 μg/l) and 5 of 6 compensated patients (71 ± 7; 56-100 μg/l). 30 The etiologic basis and functional significance of these findings remains to be determined.
The importance of the multinutrient deficiency in CHF can be further verified by another interventional study by Witte et al 42 where 30 CHF patients were randomized to receive capsules containing a combination of high-dose minerals and vitamins (calcium, magnesium, zinc, copper, selenium, vitamin A, thiamine, riboflavin, vitamin B6, folate, vitamin B12, vitamin C, vitamin E, vitamin D and coenzyme Q10) or placebo for 9 months in a double-blind fashion. All subjects were on stable optimal medical therapy for at least 3 months before enrollment. At the end of the follow-up period, left ventricular volumes were reduced in the intervention group with no change in the placebo group (-13.1% [17.1] vs. +3.8% [10.0] ; P <0.05). The left ventricular ejection fraction increased by 5.3% ± 1.4% in the intervention group and was unchanged in the placebo group (P <0.05). Furthermore, the intervention group had a significant improvement in quality of life score between enrollment and study end, whereas those taking placebo had a slight deterioration.
Summary and Conclusions
Over the past 50 years, the clinical syndrome CHF has undergone a transformation as to our understanding of its pathophysiologic expressions: from (a) a cardiocentric perspective, where myocardial contractility was the sole focus to (b) an appreciation of neurohormonal activation (the cardiorenal perspective with its salt-avidity) to (c) the current paradigm that includes each of the above together with an associated systemic component. The systemic illness of CHF features oxidative stress, a proinflammatory phenotype and a wasting of tissues. Disturbances in minerals and micronutrients are an integral feature of this illness and likely contribute to its progressive nature. These disturbances relate to chronic neurohormonal activation, as well as to environmental factors (e.g., reduced sunlight exposure and dietary Ca 2+ intake) and today's standard of care with a loop diuretic and angiotensin-converting enzyme inhibitor.
In recognizing the importance of a dyshomeostasis in Ca 2+ , Mg 2+ , vitamins D and B1, Zn and Se in CHF, its prevention and management will call into question the need for addressing these and other minerals and micronutrients in everyday practice. Based on data presented here, we feel strongly that patients with CHF need daily nutrient supplement in addition to their habitual diet. The time is at hand to focus attention on the nutritional aspects of CHF that will complement today's standard of care.
